Verastem Reports Strong Preliminary Q4/FY25 Revenue, Extends Cash Runway, and Advances Key Clinical Programs

summarizeSummary

Verastem, Inc. announced preliminary Q4 and full-year 2025 financial results, including $30.9 million in full-year product revenue, and outlined 2026 strategic priorities, extending its cash runway into the first half of 2027.

check_boxKey Events

• Preliminary Q4 and Full-Year 2025 Revenue Reported

  Verastem reported preliminary, unaudited net product revenues of approximately $17.5 million for Q4 2025 and $30.9 million for the full year 2025 for AVMAPKI FAKZYNJA CO-PACK, following its U.S. FDA approval in May 2025.

• Cash Runway Extended into First Half of 2027

  The company announced preliminary unaudited cash, cash equivalents, and investments of $205 million as of December 31, 2025. Pro-forma cash, including $29.4 million net proceeds from the exercise of expiring cash warrants, totals $234 million, extending the cash runway into the first half of 2027.

• LGSOC Program Expected to Be Self-Sustaining by H2 2026

  Verastem anticipates that the AVMAPKI FAKZYNJA CO-PACK commercial launch and development program for low-grade serous ovarian cancer (LGSOC) will become self-sustaining by the second half of 2026.

• Positive Clinical Data for LGSOC Treatment in Japan

  Updated data from the RAMP201J Phase 2 trial in Japan for LGSOC showed a confirmed overall response rate (ORR) of 38% (6/16) overall, with 57% (4/7) in KRAS-mutated LGSOC patients and 22% (2/9) in KRAS wild-type LGSOC patients.

auto_awesomeAnalysis

Verastem, Inc. delivered a comprehensive and positive update, showcasing strong initial commercial performance for AVMAPKI FAKZYNJA CO-PACK with preliminary full-year 2025 net product revenues of $30.9 million. The company significantly bolstered its financial position by exercising expiring cash warrants, netting $29.4 million, which extends its cash runway into the first half of 2027. This financial stability is further supported by the expectation that the LGSOC commercial launch and development program will become self-sustaining by the second half of 2026. Operationally, the company reported encouraging updated Phase 2 clinical data for its LGSOC treatment in Japan and outlined clear strategic priorities for 2026, including advancing its VS-7375 KRAS G12D inhibitor towards potential registration-directed trials. These updates collectively signal robust progress in both commercial execution and pipeline development, providing a strong foundation for future growth.